Market Research Logo

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Pipeline Review, H1 2016

Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Pipeline Review, H1 2016’, provides in depth analysis on Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted pipeline therapeutics.

The report provides comprehensive information on the Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)
  • The report reviews Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) Overview
Therapeutics Development
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Products under Development by Stage of Development
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Products under Development by Therapy Area
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Products under Development by Indication
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Products under Development by Companies
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Companies Involved in Therapeutics Development
Hadasit Medical Research Services & Development Ltd
VM Discovery, Inc.
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Drug Profiles
Bryostatin-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DHACP-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate PKC Epsilon for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Protein Kinase C for Type 2 Diabetes and Insulin Resistance - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMD-1201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMD-2202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Dormant Projects
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Discontinued Products
Protein Kinase C Epsilon Type (nPKC-Epsilon or EC 2.7.11.13) - Featured News & Press Releases
Mar 08, 2016: Neurotrope Announces Publication Demonstrating Synaptic Regeneration with the PKC epsilon Activator Bryostatin, in a Fragile X Disease Late Brain Development Model
Feb 11, 2016: Neurotrope Doses First Patients in Phase 2b Study of Bryostatin for Treatment of Severe Alzheimer’s Disease
Feb 03, 2016: Neurotrope Holds Investigators Meeting for U.S. Phase 2b Trial of Bryostatin-1 for Treatment of Alzheimer’s Disease
Jan 07, 2016: Neurotrope Initiates Phase 2b Study of Bryostatin for Treatment of Alzheimer’s Disease
Jul 20, 2015: Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer's Disease at the 2015 Alzheimer's Association International Conference
Jun 24, 2015: Neurotrope to Conduct Study on Niemann-Pick Type C, a Devastating Rare Pediatric Disease
Jun 12, 2015: Neurotrope to Present Findings of In-vitro Studies of Bryostatin's Effects on Niemann Pick Type C1 Cells at the Annual Michael, Marcia & Christa Parseghian Scientific Conference for Niemann-Pick Type C
Apr 16, 2015: Neurotrope Receives Research Grant From the FRAXA Research Foundation to Fund Pre-Clinical Fragile X Syndrome Behavioral Studies
Apr 09, 2015: Neurotrope Receives FDA Orphan Drug Designation for Bryostatin in the Treatment of Fragile X Syndrome
Apr 06, 2015: Neurotrope Selects Worldwide Clinical Trials to Commence Services for Phase 2B Trial of Bryostatin for the Treatment of Alzheimer's Disease
Mar 30, 2015: Severe Alzheimer's Patient Responds to Bryostatin Treatment
Mar 17, 2015: Neurotrope Announces Positive Final Results from Its Phase 2a Safety Study for the Treatment of Alzheimer’s Disease
Feb 24, 2015: Neurotrope Announces Positive Top-Line Results From Its Phase 2a Study of Bryostatin-1 in Alzheimer's Disease
Nov 20, 2014: Neurotrope Announces Last Patient Dosed in Phase 2a Clinical Trial of Bryostatin-1 for Alzheimer's Disease
Aug 18, 2014: Neurotrope’s Approach to Treating Alzheimer’s Disease Through Its Product Bryostatin-1, an Activator of Protein Kinase C Epsilon (PKCe), Supported by Blanchette Rockefeller Neurosciences Institute (BRNI) Publication, Identifying PKCe as a Biomarker of Alzheimer’s
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016
Pipeline by VM Discovery, Inc., H1 2016
Dormant Projects, H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report